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The aim of this study was to evaluate the safety of long-term treatment with tiagabine.
We reviewed the case report forms of patients with refractory partial epilepsy who took tiagabine for longer than 6 months in
two long-term studies. We classified all adverse events based on severity and persistence, and recorded the dose at onset of each
adverse event. We then divided patients into those treated for 6–12 months, 12–24 months and >24 months. We compared the
adverse event profile and change in seizure frequency among the three groups.
Forty-two patients took tiagabine for longer than 6 months. The mean duration of treatment was 22.6 months. The mean monthly
seizure frequency was 12.7 at baseline and 8.1 at study termination (36% decrease). The most common adverse events were:
tiredness (56%), headache (46%), dizziness (44%), visual symptoms (blurring, difficulty focusing, diplopia) (39%), altered
mentation (32%), and tremor (31%). The adverse event profile was comparable among the three groups. Seizure frequency was
significantly more improved in the >24 months group.
Long-term treatment with tiagabine is well tolerated. The most important predictor of long-term therapy with tiagabine was the
degree of seizure improvement.
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INTRODUCTION
Tiagabine (Gabitril) is a novel antiepileptic agent ap-
proved for use in the USA since 19971. It is a nipecotic
acid derivative with high bioavailability (90–95%),
dose-independent absorption, high protein binding
(96%), first-order elimination pharmacokinetics, and
it is metabolized extensively through the hepatic cy-
tochrome P450 enzyme system2, 3. The mechanism of
action is through selective binding to a GABA up-
take carrier (GAT-1), therefore inhibiting the reuptake
of GABA to neurons and glia4, 5. Its efficacy against
partial seizures and its side-effect profile have been
well detailed in several reports6–13. Less has been pub-
lished about the long-term use of tiagabine8–10. We
report our experience with the safety of long-term
tiagabine therapy in patients with refractory epilepsy.
MATERIALS AND METHODS
We reviewed the results of two long-term, open-
label studies of tiagabine in refractory partial epilepsy
in two centers. We concentrated on patients who
took the medication for 6 months or longer and re-
viewed their case-report forms and medical records.
We recorded age, gender, type(s) of seizures and num-
ber of antiepileptic drugs (AEDs) previously tried. We
recorded the baseline AED(s) and noted any change in
these medications during the studies. We noted seizure
frequency at baseline and at study termination. We
also recorded the duration of treatment with tiagabine
and the dose used for the longest period of time. We
looked at the maximum dose of tiagabine achieved
for each patient and the reason for its discontinuation
when applicable.
We evaluated all adverse events encountered dur-
ing the studies. We divided adverse events into ma-
jor categories based on symptoms reported. The cate-
gory of ‘tiredness’, for example, included sleepiness,
drowsiness, decreased energy, and sluggishness. The
term ‘dizziness’ encompassed vertigo, unsteadiness,
and a ‘drugged feeling’. Visual symptoms included
blurred vision, diplopia, and decreased visual focus.
Gastrointestinal symptoms included nausea, vomit-
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ing, diarrhea, constipation, and abdominal discom-
fort. Nervousness also referred to shakiness and jitters,
whereas emotional lability included feeling ‘high’ as
well as depression. The term ‘altered mentation’ in-
cluded complaints of a ‘blank feeling’, confusion,
and/or disorientation. We then classified all adverse
events based on severity (mild–moderate–severe) and
persistence (transient–persistent). We also recorded
the dose of tiagabine at the onset of each adverse event.
We then divided the patients into three groups based
on the duration of treatment with tiagabine; patients
who took the drug for 6–12 months (19 patients, mean
duration of treatment = 8 months), patients who took
the drug for 12–24 months (6, mean duration of treat-
ment = 15 months), and those who took the drug for
greater than 24 months (17, mean duration of treat-
ment = 43 months). The two largest groups were
those who took the drug for 6–12 months and greater
than 24 months. We compared these two groups for
age, gender, number of AEDs previously tried, num-
ber of AEDs at baseline, and change in AEDs dur-
ing the studies as well as seizure frequency at baseline
and study termination. We also compared the adverse
event profile among the two groups, including the dose
at onset, frequency, and persistence.
We used the chi-squared method and Fisher’s exact
test for statistical analysis.
RESULTS
A total of 59 patients in two centers received tiagabine
as a part of various studies of the treatment of partial
seizures. Four patients who participated in the double-
blind phase of a dose–response trial exited without en-
rollment in the long-term, open-label extension of the
study. The other 55 patients participated in two long-
term studies of tiagabine in the treatment of refrac-
tory partial seizures. Forty-two of those 55 patients
(76%) took tiagabine for longer than 6 months and
constituted the study population. There were 24 fe-
males and 18 males; the mean age was 36 years (range:
13–70). They had previously tried an average of 5.5
AEDs prior to enrollment in a tiagabine study. The
most common baseline AEDs were carbamazepine
(21 patients), phenytoin (16 patients) and divalproex
sodium (ten patients). At baseline, 26 patients were on
one AED, 14 were on two AEDs, and one patient was
on three AEDs. Twenty-nine of 42 patients remained
on the same baseline AEDs during the course of the
study. Of these 29 patients, 19 were on one AED, nine
were on two AEDs, and one was on three. Among the
other 12 patients, five were on two AEDs and reduced
to one drug, four were on one AED and changed to a
different drug, one was on one AED and changed to a
different drug and two patients were on one AED and
added another drug.
The mean duration of treatment with tiagabine
was 22.5 months for all patients. The mean dose
of tiagabine that patients took for the longest time
was 49 mg d−1. The dose of tiagabine taken for the
longest period of time did not necessarily represent
the highest dose achieved; the mean maximal dose was
59 mg d−1. The mean monthly seizure frequency was
12.7 at baseline and 8.1 at the end of follow-up, this
represented a 36% decrease in seizure frequency. The
median monthly seizure frequency was seven at base-
line and four at the end of follow-up (43% decrease).
The most common adverse events were tiredness,
headache, dizziness, visual symptoms, altered menta-
tion, tremor, memory problems, gastrointestinal symp-
toms, nervousness, paresthesias, and emotional labil-
ity (Table 1). Less common adverse events were in-
somnia (four patients), decreased concentration (three
patients), tinnitus (three patients), auditory hallucina-
tions (one patient), generalized stiffness (one patient),
and speech disturbance (one patient). Adverse events
were mostly mild to moderate in intensity and tran-
sient in nature. Reducing tiagabine or concomitant
AED doses relieved most adverse events. Only three
patients discontinued the medication because of ad-
verse events.
One particular adverse event, altered mentation, oc-
curred in 13 patients (32%). This was generally de-
scribed as episodes of confusion or a blank feeling.
Four patients had associated decreased responsive-
ness and subtle twitching of one or more limbs, which
started at a mean dose of 51 mg d−1. An EEG ob-
tained in two of these patients showed concomitant
generalized bisynchronous rhythmic slow wave activ-
ity. No patient acutely responded to repeated doses
of benzodiazepines. One patient consequently discon-
tinued tiagabine. The others had significant reduction
in seizure frequency and as a result only reduced the
dose of tiagabine (two patients) or the concomitant
AED (one patient) with improvement or resolution of
symptoms.
Comparison of the two largest groups of patients
(6–12 months and greater than 24 months) revealed
similar demographic data (Table 2). The only major
difference was the degree of improvement in seizure
control, which was significantly in favor of the greater
than 24 months groups. The adverse event profile was
also generally comparable among the two groups (Ta-
ble 3). Only emotional lability occurred significantly
more frequently in the greater than 24 months group.
DISCUSSION
We report our experience with long-term treatment of
refractory epilepsy with tiagabine. In our series, 76%
of patients with refractory epilepsy who were exposed
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Table 1: Adverse events with long-term tiagabine therapy.
Adverse event Number of Severity Persistence Mean onset
patients Mild Moderate Severe Transient Persistent dose (mg d−1)
Tiredness 23 17 5 1 18 5 40
Headache 19 11 7 1 11 8 30
Dizziness 18 12 6 0 14 4 43
Visual symptoms 16 13 3 0 13 3 36
Altered mentation 13 7 5 1 11 2 50
Tremor 13 11 2 0 8 5 36
Memory problems 9 6 3 0 2 7 41
GI symptoms 8 8 0 0 7 1 42
Nervousness 8 4 3 1 7 1 37
Paresthesias 7 5 1 1 4 3 30
Emotional lability 6 6 0 0 5 1 47
Table 2: Comparison of the three treatment groups for age, seizure control and tiagabine (TGB) dose.
Length of Number of Mean age Mean Prior # Baseline End seizure % change Maximum Longest TGB
treatment patients (years) duration of AEDs seizure frequency TGB dose dose (mg d−1)
(months) (months) treatment frequency (mg d−1)
6–12 19 41 8 5 10.2 9.1 10.9 52 44
12–24 6 32 15 6.5 9.3 4.8 47.8 70 61
>24 17 32 43 6.3 16.6 8 52 64 49
P value NS NS NS NS NS 0.006 NS NS
to tiagabine and entered an extension study continued
the medication for longer than 6 months. The most
common adverse events related to the central nervous
system and were tiredness, headache, dizziness, vi-
sual symptoms, altered mentation, tremor, and mem-
ory problems. They were, therefore, generally com-
parable to previous reports6–13. All but one of our
patients were on at least one other AED, and one of the
disadvantages of add-on trials is the tendency to over-
estimate adverse events14. However, the safety profile
of tiagabine has been similar in both add-on6, 8–13 and
monotherapy studies7. Overall, in the clinical trials,
21% of patients discontinued the medication because
of adverse events, most commonly dizziness, somno-
lence, depression, confusion, and asthenia2. Our find-
ings are somewhat similar, with dizziness, decreased
memory, altered mentation and headache causing dis-
continuation of the drug after long-term therapy in
three patients (7%). The smaller number of patients
discontinuing the drug because of adverse events in
our series may reflect the open-label nature of the
trials where frequent adjustments of doses of medi-
cations are possible. In addition, only patients who
were treated for 6 months or more were included in
this study, and adverse effects resulting in discontin-
uation may be more likely early in therapy. Adverse
events were mostly mild to moderate in severity, tran-
sient in nature, and occurred at relatively large doses
of tiagabine. In fact, the mean daily dose of tiagabine
used for the longest period of times was 49 mg, which
approaches the higher end of the recommended dose
range (32–56 mg d−1) for patients on concurrent hep-
atic enzyme-inducing AEDs15.
One specific adverse event, altered mentation, has
received particular attention with some reports sug-
gesting that it may represent a form of non-convulsive
status epilepticus (NCSE)16–19. The evidence for
NCSE was given in some case reports of NCSE in
association with TGB therapy16–19. In some instances
there was no EEG confirmation of the suspected di-
agnosis16, and where the EEG was performed during
the episode the published figures can be interpreted as
showing bisynchronous slow wave activity consistent
with encephalopathy17–19. NCSE may be a rare occur-
rence with TGB therapy20 comparable in incidence
to other cohorts of patients with epilepsy followed
over a long period of time21. Our experience sug-
gests that in the majority of patients this adverse event
may represent a dose-related encephalopathic state
due to intolerance of tiagabine itself or in combination
with other AEDs rather than NCSE. Abou-Khalil22
reported two patients with prolonged episodes of al-
tered mental status, twitching of upper extremities and
concomitant EEG showing rhythmic generalized slow
waves intermixed with sharp waves and no response
to lorazepam in one. Both patients were then mon-
itored with continuous video-EEG following with-
drawal of their AEDs; both had only non-epileptic
spells and no evidence for epilepsy. This further sug-
gests that the manifestations reported represent an en-
cephalopathic state induced by tiagabine rather than
NCSE.
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Table 3: Comparison of the three treatment groups for adverse events.
Length of Tiredness Headache Dizziness Vis Alt Tremor Memory GI Paresthesias Emotional Nervousness
treatment sxs MS sxs lability
6–12 months 53 37 37 32 32 32 32 11 11 0 5
12–24 months 67 50 83 50 0 33 0 33 33 33 33
>24 months 53 53 35 35 35 29 18 24 18 24 29
P value NS NS NS NS NS NS NS NS NS 0.04 NS
Results are expressed as percentage of patients experiencing side-effects. Vis sxs, visual symptoms; Alt MS, altered mentation;
GI sxs, gastrointestinal symptoms.
Another group of adverse effects that are of interest
are the visual symptoms. Vigabatrin, another GABA-
ergic agent has been associated with visual field con-
striction, as well as other manifestations reflecting reti-
nal toxicity. Our patients experienced visual symp-
toms commonly encountered with other AEDs, mainly
blurring of vision, difficulty focusing, and diplopia.
There are now two reports indicating lack of occur-
rence of visual constriction with long-term use of
tiagabine22, 23.
An interesting finding in our study was the similar-
ity of adverse events encountered in patients who took
tiagabine for 6–12 months and those who took it for
longer than 2 years. There was no significant differ-
ence in the safety profile among the two groups both
in terms of the types and frequency of individual ad-
verse events. Emotional lability, which seemed to oc-
cur more frequently in the longer treated group, was
mostly transient (75%). Longer duration of treatment
with tiagabine, therefore, generally does not seem to
predispose patients to greater frequency or severity of
adverse events. Patients who took the medication for
greater than 2 years had significantly less seizures than
those who took it for 6–12 months (52% vs. 10.9%
reduction, respectively). Therefore, the degree of im-
provement in seizure control and not adverse events
was the most important predictor of long-term therapy
with tiagabine in our group.
Although the safety of tiagabine was recently re-
ported in detail10, our study adds valuable informa-
tion. We emphasized long-term therapy (>6 months)
and found that it did not result in emergence of new,
unexpected adverse events. We found that long-term
treatment with relatively high doses of tiagabine is
well tolerated in patients with refractory epilepsy. We
also compared the safety and efficacy of tiagabine
among patients with variable duration of exposure to
the agent and found that long-term therapy was mostly
dependent on improvement of seizure frequency. Con-
tinued assessment of long-term safety is important for
all new AEDs. The absence of cumulative or unex-
pected late toxicity will improve neurologists’ comfort
level with the use of these agents.
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